


Status: Currently Official on 16-Feb-2025  
 Official Date: Official as of 01-May-2020  
 Document Type: USP Monographs  
 DocId: GUID-57D8D35F-C692-49F8-A57D-4607427930BF\_2\_en-US  
 DOI: [https://doi.org/10.31003/USPNF\\_M82750\\_02\\_01](https://doi.org/10.31003/USPNF_M82750_02_01)  
 DOI Ref: eu557

© 2025 USPC  
 Do not distribute

# Thimerosal



$C_9H_9HgNaO_2S$  404.81  
 Mercury, ethyl(2-mercaptobenzoato-S)-, sodium salt;  
 Ethyl (sodium o-mercaptobenzoato)mercury CAS RN®: 54-64-8.

## DEFINITION

Thimerosal contains NLT 97.0% and NMT 102.0% of thimerosal ( $C_9H_9HgNaO_2S$ ), calculated on the dried basis.

## IDENTIFICATION

**Change to read:**

- **A.** [▲ SPECTROSCOPIC IDENTIFICATION TESTS \(197\), Infrared Spectroscopy: 197K ▲](#) (CN 1-MAY-2020)
- **B.**  
**Sample solution:** 10 mg/mL  
**Analysis:** To the *Sample solution* add a few drops of silver nitrate TS.  
**Acceptance criteria:** A pale yellow precipitate is formed.
- **C.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

## ASSAY

### PROCEDURE

**Solution A:** 0.05% Trifluoroacetic acid, prepared by adding 1.0 mL of trifluoroacetic acid to 2 L of water

**Mobile phase:** Methanol and *Solution A* (60:40)

**Standard stock solution:** 250 µg/mL of [USP Thimerosal RS](#) in water

**Impurity stock solution:** 250 µg/mL of [USP Thimerosal Related Compound A RS](#) in methanol and water (90:10)

**System suitability solution:** 25 µg/mL each of [USP Thimerosal RS](#) and [USP Thimerosal Related Compound A RS](#) from *Standard stock solution* and *Impurity stock solution*, respectively, in water

**Standard solution:** 25 µg/mL of [USP Thimerosal RS](#) in water from *Standard stock solution*

**Sample solution:** 25 µg/mL of Thimerosal in water

[NOTE—Prepare both the *Standard solution* and *Sample solution* at a concentration of NMT ±10% of the specified concentration.]

### Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

**Mode:** LC

**Detector:** UV 222 nm

**Column:** 2.1-mm × 10-cm; 2-µm packing L1

**Autosampler temperature:** 4°

**Flow rate:** 0.35 mL/min

**Injection volume:** 2.5 µL

### System suitability

**Samples:** *System suitability solution* and *Standard solution*

[NOTE—The relative retention times of thimerosal and thimerosal related compound A are 1.0 and 1.3, respectively.]

### Suitability requirements

**Resolution:** NLT 3.5 between the thimerosal and thimerosal related compound A peaks, *System suitability solution*

**Tailing factor:** NMT 1.5, *Standard solution*

**Relative standard deviation:** NMT 0.73%, *Standard solution*

#### Analysis

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of thimerosal ( $C_9H_9HgNaO_2S$ ) in the portion of Thimerosal taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

$r_U$  = peak response from the *Sample solution*

$r_S$  = peak response from the *Standard solution*

$C_S$  = concentration of [USP Thimerosal RS](#) in the *Standard solution* (µg/mL)

$C_U$  = concentration of Thimerosal in the *Sample solution* (µg/mL)

**Acceptance criteria:** 97.0%–102.0% on the dried basis

#### IMPURITIES

##### • MERCURY IONS

**Iodide reagent:** 332 mg/mL of potassium iodide. Prepare fresh daily. Keep the stopper in the flask, and protect from light.

**Standard solution:** 95 µg/mL of mercuric chloride

**Sample stock solution:** 5 mg/mL of Thimerosal

**Sample solution A:** 1 mg/mL of Thimerosal from *Sample stock solution*

**Sample solution B:** 1 mg/mL of Thimerosal from *Sample stock solution* and 9.5 µg/mL of mercuric chloride from *Standard solution*

##### Instrumental conditions

**Mode:** UV

**Analytical wavelength:** Determine the wavelength of maximum absorbance for the tetraiodomercurate ion at about 323 nm using the solution prepared by mixing 1.0 mL of the *Standard solution* and 5.0 mL of the *Iodide reagent*, and diluting with water to 10.0 mL.

**Cell:** 1 cm

**Blank:** Water

##### Analysis

Protect all solutions from light before determining their absorbances.

**Samples:** Label five 10-mL volumetric flasks C, D, E, F, and R. Transfer 5.0 mL of *Sample solution A* to flasks C and D, 5.0 mL of *Sample solution B* to flasks E and F, and 5.0 mL of water to flask R. Dilute flasks C and E with water to volume. Dilute flasks D, F, and R with *Iodide reagent* to volume.

Determine the absorbances of the solutions in flasks C, D, E, F, and R as  $A_C$ ,  $A_D$ ,  $A_E$ ,  $A_F$ , and  $A_R$ , respectively.

Calculate the percentage of mercury ions in the portion of Thimerosal taken:

$$\text{Result} = (A_U/A_S) \times (C_S/C_U) \times (A_r/M_r) \times 100$$

$A_U$  = absorbance of the *Sample solution* obtained by:  $A_U = A_D - A_R - A_C$

$A_S$  = absorbance of the *Standard solution* obtained by:  $A_S = A_F - A_R - A_E - A_U$

$C_S$  = concentration of mercuric chloride in *Sample solution B* (mg/mL)

$C_U$  = concentration of Thimerosal in *Sample solution B* (mg/mL)

$A_r$  = atomic weight of mercury, 200.59

$M_r$  = molecular weight of mercuric chloride, 271.50

**Acceptance criteria:** NMT 0.70%

##### • ORGANIC IMPURITIES

**Solution A:** 0.05% Trifluoroacetic acid, prepared by adding 1.0 mL of trifluoroacetic acid to 2 L of water

**Mobile phase:** Methanol and *Solution A* (60:40)

**Stock solution 1:** 250 µg/mL of [USP Thimerosal RS](#) in water

**Stock solution 2:** 250 µg/mL of [USP Thimerosal Related Compound A RS](#) in methanol and water (90:10)

**System suitability solution:** 25 µg/mL each of [USP Thimerosal RS](#) and [USP Thimerosal Related Compound A RS](#) from *Stock solution 1* and *Stock solution 2*, respectively, in water

**Standard solution:** 0.25 µg/mL of [USP Thimerosal Related Compound A RS](#) from *Stock solution 2* in water

**Sample solution:** 250 µg/mL of Thimerosal in water

#### Chromatographic system

(See [Chromatography \(621\)](#), [System Suitability](#).)

**Mode:** LC

**Detector:** UV 222 nm

**Column:** 2.1-mm × 10-cm; 2-µm packing L1

**Autosampler temperature:** 4°

**Flow rate:** 0.35 mL/min

**Injection volume:** 2.5 µL

#### System suitability

**Samples:** *System suitability solution* and *Standard solution*

#### Suitability requirements

**Resolution:** NLT 3.5 between the thimerosal and thimerosal related compound A peaks, *System suitability solution*

**Relative standard deviation:** NMT 3%, *Standard solution*

#### Analysis

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of each impurity in the portion of Thimerosal taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

$r_U$  = peak response of each impurity from the *Sample solution*

$r_S$  = peak response of thimerosal related compound A from the *Standard solution*

$C_S$  = concentration of [USP Thimerosal Related Compound A RS](#) in the *Standard solution* (µg/mL)

$C_U$  = concentration of Thimerosal in the *Sample solution* (µg/mL)

**Acceptance criteria:** See [Table 1](#). Disregard peaks less than 0.05%.

**Table 1**

Name	Relative Retention Time	Acceptance Criteria, NMT (%)
Thiosalicylic acid <sup>a</sup>	0.36	0.10
Thimerosal	1.0	—
Thimerosal related compound A	1.3	0.10
Any other individual unspecified impurity	—	0.10
Total impurities	—	1.0

<sup>a</sup> 2-Sulfanylbobenzoic acid.

#### SPECIFIC TESTS

- [Loss on Drying \(731\)](#).

**Analysis:** Dry to constant weight under vacuum over phosphorus pentoxide.

**Acceptance criteria:** NMT 0.5%

#### ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in tight, light-resistant containers.
- [USP REFERENCE STANDARDS \(11\)](#).

[USP Thimerosal RS](#)  
[USP Thimerosal Related Compound A RS](#)  
2,2'-Disulfanediyldibenzoic acid.  
 $C_{14}H_{10}O_4S_2$  306.35

**Auxiliary Information** - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
THIMEROSAL	<a href="#">Documentary Standards Support</a>	SM12020 Small Molecules 1
REFERENCE STANDARD SUPPORT	RS Technical Services <a href="mailto:RSTECH@usp.org">RSTECH@usp.org</a>	SM12020 Small Molecules 1

**Chromatographic Database Information:** [Chromatographic Database](#)

**Most Recently Appeared In:**

Pharmacopeial Forum: Volume No. PF 40(5)

**Current DocID:** GUID-57D8D35F-C692-49F8-A57D-4607427930BF\_2\_en-US

**DOI:** [https://doi.org/10.31003/USPNF\\_M82750\\_02\\_01](https://doi.org/10.31003/USPNF_M82750_02_01)

**DOI ref:** [eu557](#)

OFFICIAL